INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Contingent Liabilities History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹2.91 Cr | ₹1.17 Cr | ₹0.98 Cr | ₹0.95 Cr | ₹0.67 Cr |
What is the latest Contingent Liabilities ratio of INDO US BIOTECH ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹2.91 Cr |
| Mar2025 | ₹1.17 Cr |
| Mar2024 | ₹0.98 Cr |
| Mar2023 | ₹0.95 Cr |
| Mar2022 | ₹0.67 Cr |
How is Contingent Liabilities of INDO US BIOTECH Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹2.91 Cr | 148.68 | |
| Mar2025 | ₹1.17 Cr | 19.86 | |
| Mar2024 | ₹0.98 Cr | 2.84 | |
| Mar2023 | ₹0.95 Cr | 42.64 | |
| Mar2022 | ₹0.67 Cr | - | |
Compare Contingent Liabilities of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹127.6 Cr | -13.1% | -17.6% | -47.5% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹3,763.8 Cr | 0% | 4.5% | -30.8% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,230.8 Cr | -6.9% | -5.4% | 11.3% | Stock Analytics | |
| AVT NATURAL PRODUCTS | ₹1,340.7 Cr | -12.8% | -10.5% | 28.8% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹870.7 Cr | -12.7% | -1.4% | NA | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹560.9 Cr | -0.2% | 9.7% | 11.3% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | -13.1% |
-17.6% |
-47.5% |
| SENSEX | -1.6% |
-2.3% |
-11.5% |
You may also like the below Video Courses